Cost-effectiveness of 12-month assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS Trial)

Karow, A, Reimer, J, Konig, HH, Heider, D, Bock, T, Huber, C, Schottle, D, Meister, K, Rietschel, L, Ohm, G, Schulz, H, Naber, D, Schimmelmann, Benno G, Lambert, M

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
22490266

DOI
10.4088/JCP.11m06875

Indexing Status
Subject indexing assigned by NLM

MeSH
Adolescent; Adult; Aged; Antipsychotic Agents /administration & dosage /economics /therapeutic use; Combined Modality Therapy /economics /methods /statistics & numerical data; Cost-Benefit Analysis /statistics & numerical data; Dibenzothiazepines /administration & dosage /economics /therapeutic use; Female; Germany; Humans; Male; Middle Aged; Psychotherapy /economics /methods; Quetiapine Fumarate; Schizophrenia /drug therapy /economics /therapy

AccessionNumber
22013039101

Date bibliographic record published
25/07/2014